Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acura Pharmaceuticals, Inc. (ACUR)

0.0004   -0 (-33.33%) 08-01 09:32
Open: 0.0004 Pre. Close: 0.0006
High: 0.0004 Low: 0.0004
Volume: 262 Market Cap: 0(M)

Technical analysis

as of: 2023-05-19 4:34:31 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 0.05     One year: 0.06
Support: Support1: 0.04    Support2: 0.03
Resistance: Resistance1: 0.05    Resistance2: 0.05
Pivot: 0.05
Moving Average: MA(5): 0.05     MA(20): 0.05
MA(100): 0.05     MA(250): 0.13
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 1     %D(3): 0
RSI: RSI(14): 89.1
52-week: High: 0.55  Low: 0
Average Vol(K): 3-Month: 6 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACUR ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.05 - 0.05 0.05 - 0.05
Low: 0.05 - 0.05 0.05 - 0.05
Close: 0.05 - 0.05 0.05 - 0.05

Company Description

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Headline News

Mon, 14 Feb 2022
Acura Pharmaceuticals Provides Development Update on LTX-03 - GlobeNewswire

Tue, 10 Jul 2018
Know Labs Stock Forecast, Price & News (OTCMKTS:KNWN) - MarketBeat

Wed, 15 Nov 2017
Acura Pharmaceuticals Stock Forecast, Price & News (OTCMKTS ... - MarketBeat

Mon, 10 Dec 2012
Acura Pharmaceuticals Launches Next Generation Cold Medicine ... - Pharmaceutical Online

Tue, 13 Mar 2012
Should You 'Sell The News' In Biotech Stocks? - Seeking Alpha

Mon, 20 Jun 2011
Pfizer, Acura Painkiller Approved by FDA - TheStreet

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  PNK
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 65 (M)
Shares Float 61 (M)
% Held by Insiders 5.5 (%)
% Held by Institutions 3 (%)
Shares Short 90 (K)
Shares Short P.Month 76 (K)

Stock Financials

EPS -0.03
EPS Est Next Qtl 0
EPS Est This Year -0.47
EPS Est Next Year 0.37
Book Value (p.s.) 0
Profit Margin (%) -51.3
Operating Margin (%) -49.4
Return on Assets (ttm) -38.5
Return on Equity (ttm) 0
Qtrly Rev. Growth -34.1
Gross Profit (p.s.) 0.02
Sales Per Share 0.03
EBITDA (p.s.) -0.02
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.67
PEG Ratio 0
Price to Book value 0
Price to Sales 1.44
Price to Cash Flow -8.22

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.